Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19
Top Cited Papers
- 15 June 2020
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (8), 843-856
- https://doi.org/10.1002/phar.2438
Abstract
A hyperinflammatory response to SARS‐CoV‐2 infection, reminiscent of cytokine release syndrome, has been implicated in the pathophysiology of acute respiratory distress syndrome and organ damage in patients with COVID‐19. Agents that inhibit components of the pro‐inflammatory cascade have garnered interest as potential treatment options with hopes that dampening the pro‐inflammatory process may improve clinical outcomes. Baricitinib is a reversible Janus‐associated kinase (JAK)‐inhibitor that interrupts the signaling of multiple cytokines implicated in COVID‐19 immunopathology. It may also have antiviral effects by targeting host factors that viruses rely for cell entry and by suppressing type I interferon driven angiotensin‐converting‐enzyme‐2 up regulation. However, baricitinib’s immunosuppressive effects may be detrimental during acute viral infections by delaying viral clearance and increasing vulnerability to secondary opportunistic infections. The lack of reliable biomarkers to monitor patients’ immune status as illness evolves complicates deployment of immunosuppressive drugs like baricitinib. Furthermore, baricitinib carries the risk of increased thromboembolic events which is concerning given the proclivity towards a hyper‐coagulable state in COVID‐19 patients. In this article we review available data on baricitinib with an emphasis on immunosuppressive and antiviral pharmacology, pharmacokinetics, safety and current progress in COVID‐19 clinical trials.Keywords
This publication has 66 references indexed in Scilit:
- Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and CanadaPLOS ONE, 2013
- Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approachThe Lancet Infectious Diseases, 2013
- Drotrecogin Alfa (Activated) in Adults with Septic ShockThe New England Journal of Medicine, 2012
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathwayCell Research, 2008
- Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail DeletedJournal of Virology, 2007
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003
- Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shockThe Lancet, 1998
- CDP571, a humanized antibody to human tumor necrosis factor-alphaCritical Care Medicine, 1995
- Corticosteroid treatment for sepsisCritical Care Medicine, 1995